By developing slow release, crystal forms of drugs that block the CSF1R immune pathway and encapsulating them with insulin producing cells in alginate spheres, the Anderson/Langer group can reduce immune reactions that lead to biomedical implant failure and ensure stable, long-term glycemic control in models of diabetes. Early versions of this technology appear in the KI Image Awards Archive; a recent Science Translational Medicine study highlights contexts where the approach could be successful.